Trials / Withdrawn
WithdrawnNCT05697029
Tetrandrine Tablets Used in Hospitalized Adults With COVID-19
Tetrandrine Tablets Used in Hospitalized Adults With COVID-19: a Double-blind, Placebo-controlled, Randomised Trial
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Peking University Third Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effectiveness of tetrandrine tablets in preventing the progression of COVID-19 from severe to critical.
Detailed description
The primary objective of this study is to evaluate the effectiveness of tetrandrine tablets in preventing the progression of COVID-19 from severe to critical. The secondary objective is to evaluate the clinical indicators of COVID-19 with tetrandrine tablets treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tetrandrine | tetrandrine TID for 28 days |
Timeline
- Start date
- 2023-12-31
- Primary completion
- 2025-12-12
- Completion
- 2025-12-12
- First posted
- 2023-01-25
- Last updated
- 2024-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05697029. Inclusion in this directory is not an endorsement.